2022
Early human B cell signatures of the primary antibody response to mRNA vaccination
Kardava L, Rachmaninoff N, Lau W, Buckner C, Trihemasava K, Blazkova J, de Assis F, Wang W, Zhang X, Wang Y, Chiang C, Narpala S, McCormack G, Liu C, Seamon C, Sneller M, O’Connell S, Li Y, McDermott A, Chun T, Fauci A, Tsang J, Moir S. Early human B cell signatures of the primary antibody response to mRNA vaccination. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2204607119. PMID: 35759653, PMCID: PMC9282446, DOI: 10.1073/pnas.2204607119.Peer-Reviewed Original ResearchConceptsMemory B cellsAntibody responseDose 2MBC populationsB cellsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Durability of antibodiesSubsequent antibody levelsB cell signaturesIgG antibody responsePrimary antibody responseSyndrome coronavirus 2Weak antibody responseMessenger RNA vaccinesPlasmablast frequencyFirst doseMRNA vaccinationMonth 6Antibody levelsProtective immunitySecond dosesAntibody titersCoronavirus 2SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
Liew J, Gianfrancesco M, Harrison C, Izadi Z, Rush S, Lawson-Tovey S, Jacobsohn L, Ja C, Hyrich K, Gossec L, Strangfeld A, Carmona L, Schäfer M, Frãzao-Mateus E, Bulina I, Stafford F, Tufan A, Graver C, Yardımcı G, Zepa J, Al Emadi S, Cook C, Abutiban F, Dey D, Katigbak G, Kaufman L, Kowalski E, Martínez-Martínez M, Patel N, Reyes-Cordero G, Salido E, Smith E, Snow D, Sparks J, Wise L, Bhana S, Gore-Massy M, Grainger R, Hausmann J, Sirotich E, Sufka P, Wallace Z, Machado P, Robinson P, Yazdany J. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open 2022, 8: e002187. PMID: 35387864, PMCID: PMC8987210, DOI: 10.1136/rmdopen-2021-002187.Peer-Reviewed Original ResearchConceptsB-cell depleting therapyBreakthrough infectionsRheumatic diseasesSARS-CoV-2Clinical characteristicsSARS-CoV-2 breakthrough infectionsPre-existing lung diseaseSARS-CoV-2 infectionBreakthrough COVID-19Cell-depleting therapyTwo-dose seriesTime of vaccinationSecond vaccine doseHigh-risk populationMessenger RNA vaccinesCOVID-19 symptomsSingle-dose vaccineCOVID-19Vaccination seriesSystemic glucocorticoidsVaccine doseVaccine effectivenessSecond doseVaccinated individualsLung disease
2021
COVID-19 Vaccination–Associated Myocarditis in Adolescents
Jain SS, Steele JM, Fonseca B, Huang S, Shah S, Maskatia SA, Buddhe S, Misra N, Ramachandran P, Gaur L, Eshtehardi P, Anwar S, Kaushik N, Han F, Chaudhuri NR, Grosse-Wortmann L. COVID-19 Vaccination–Associated Myocarditis in Adolescents. 2021, 148: e2021053427. PMID: 34389692, DOI: 10.1542/peds.2021-053427.Peer-Reviewed Original ResearchConceptsCardiovascular magnetic resonanceMultisystem inflammatory syndromeMyocardial tissue changesInflammatory syndromeVentricular dysfunctionMyocardial injuryTissue changesExcellent short-term outcomesMild left ventricular dysfunctionDifferent pediatric age groupsQuick clinical recoveryLeft ventricular dysfunctionResolution of symptomsRetrospective multicenter studyPediatric age groupShort-term outcomesShort-term prognosisMessenger RNA vaccinesLate gadolinium enhancementYears of ageLake Louise criteriaSignificant dysrhythmiasHospital courseClinical characteristicsClinical recovery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply